Introduction: Inhibition of programmed cell death-1 (PD-1) and its ligand programmed death ligand 1 (PD-L1) by using an immune checkpoint inhibitor has emerged as a promising immunotherapy for NSCLC. The correlation of PD-L1 expression in tumor cells with treatment outcomes has been reported in many pivotal trials; however, the relationship remains unclear. Here, we demonstrate that those patients with both high density of PD-1-positive CD8 and PD-L1-positive CD4-positive CD25-positive (PD-1
Conclusions: Our findings suggested that the density of PD-L1-positive CD4-positive CD25-positive Tregs in the tumor microenvironment can serve as a diagnostic factor to supplement PD-L1 expression in tumor cells and predict the response to PD-1/PD-L1 blockade immunotherapy in NSCLC.
Introduction
Programmed cell death 1 (PD-1) and its ligand programmed death ligand 1 (PD-L1) play a pivotal role in tumor evasion, and PD-1/PD-L1 blockade has shown a durable antitumor effect in NSCLC. [1] [2] [3] The PD-1 human monoclonal antibody (mAb) pembrolizumab has shown antitumor activity in advanced NSCLC when PD-L1 expression is detected in more than 50% of tumor cells. 2 However, a clinical trial of the PD-1 mAb nivolumab showed that expression of PD-L1 in cancer cells is not a prognostic factor in nonsquamous NSCLC. 3 In melanoma, patients with PD-L1-positive tumors have a better response to nivolumab (PD-1 antibody) than those with negative PD-L1 expression. 4 Therefore, PD-L1 protein expression alone in tumor cells is not an accurate indicator to identify patients who might respond to PD-1/PD-L1 blockade immunotherapy; the genomic landscape and the frequencies of tumor-infiltrating lymphocytes (TILs) and cytokines in tumor tissue could also influence the immune response. 5 To study TILs in the microenvironment of NSCLC, we first collected and analyzed 42 large (10-mm 3 ) fresh, surgically resected NSCLC specimens and identified a subset of high-PD-L1-expressing CD25-positive CD4-positive T cells (PD-L1 hi regulatory T cells [Tregs] ) in the tumor microenvironment by flow cytometry (FCM), immunohistochemistry (IHC), and immunofluorescence (IF) staining assay. We found that the frequency of PD-L1 hi Tregs was positively correlated with high-PD-1-expressing CD8 (PD-1 hi CD8) in TILs. In addition, the patients with both high frequencies of PD-1 hi CD8 and PD-L1
hi Tregs in the tumor microenvironment showed a greater PD-1/PD-L1 pathway dependence in CD8 T-cell exhaustion. In our in vitro studies, the PD-1/PD-L1 antibody induced a greater cancer cell-killing effect of TILs from the tissue samples with both PD-1 hi CD8 and PD-L1
hi Tregs. The PD-1/PD-L1 antibody induced a greater cell killing effect of TILs from the PD-1 hi PD-L1 hi group in the high-PD-L1-expressing cell line PC9 than in the low-PD-L1-expressing cell line H23. Moreover, after immunologic classification in 31 patients receiving PD-1 blockade immunotherapy according to the PD-L1 Tregs and PD-1 TILs' heterogeneity distribution, we found that the patients with a high density of PD-1 hi CD8 and PD-L1
hi Tregs in the tumor microenvironment showed a better response among PD-L1-positive patients (!1% PD-L1 expression in tumor cells). Our findings suggested that the preexisting PD-1 hi CD8 and PD-L1 hi TILs in the tumor microenvironment can act as a diagnostic factor to supplement PD-L1 expression in tumors cells and predict the response to PD-1/PD-L1 blockade immunotherapy.
TILs play an important role in the clinical outcome of human cancer. [6] [7] [8] The tumor microenvironment is a complex system with multiple subsets of TILs, including different kinds of Tregs and CD8-positive T lymphocytes that maintain the immunologic balance in the tumor. 9, 10 However, despite the reported association between TILs and clinical outcome, 7, 8 the relationship between PD-1/ PD-L1 blockade response and different TILs remains unclear. Cancers are caused by somatic mutations, and the mutations in cancer can lead to the exposure of neoantigens, allowing tumors to be recognized as foreign by the immune system. [11] [12] [13] However, tumors can escape the immune system through maintenance of an immunosuppressive microenvironment.
14 The PD-1/PD-L1 pathway plays an important role in blocking the immune response. Inhibition of the PD-1/PD-L1 pathway inhibits T-cell proliferation and the secretion of cytotoxic mediators, and increases tumor cell killing by CD8 T-effector cells. 15 PD-L1 is expressed in NSCLC, and the interaction of PD-1 with PD-L1 inhibits T-cell activation and promotes tumor immune escape. 16 Despite evidence suggesting that inhibition of the PD-1/PD-L1 pathway by PD-1 or PD-L1 immune checkpoint inhibitor antibodies enhances anticancer immune responses, the relationship between PD-1/PD-L1 blockade and different TILs remains unclear. 2, 3 The density of TILs has been confirmed as an important factor predicting outcome in patients with cancer, 17, 18 especially Tregs and CD8-positive TILs. CD8 T-effector cells within a tumor are recognized as positive prognostic factors in NSCLC. 19 However, in tumors, CD8 T-effector cells become exhausted and unable to proliferate and kill tumor cells. 20 Because PD-L1 is expressed in tumor cells and TILs in tumor tissue, the interaction with PD-1 on TILs can lead to inhibition of CD8 T-effector cells. The expression of PD-1 or PD-L1in TILs could lead to CD8 T-effector cell exhaustion and limit antitumor functions, decreasing the response of PD-1 or PD-L1 blockade immunotherapy. 21 Tregs are important in suppressing immune responses during tumorigenesis. 22 PD-L1 is also expressed on Tregs to inhibit the effector T cells through binding to PD-1. 23 However, the role of PD-L1-expressing TILs in the tumor microenvironment remains unclear. We showed that PD-L1
hi TILs were positively associated with the frequency of PD-1 hi CD8 T-effector cells in the tumor microenvironment. Our study suggested an immune classification in NSCLC according to the density of PD-1-positive CD8 and PD-L1-positive CD25-positive CD4-positive in the tumor microenvironment. In addition, we found that the patients with both high density of PD-1-positive CD8 Teffector cells and PD-L1-positive CD25-positive CD4 TILs (PD-1 hi PD-L1 hi ) in the tumor microenvironment showed a greater cancer cell killing effect of effector CD8-positive T cells after PD-1/PD-L1 blockade immunotherapy. Our findings suggest that the density of preexisting PD-1 hi PD-L1 hi in the tumor microenvironment can serve as a diagnostic factor to predict the response to PD-1/PD-L1 blockade immunotherapy.
Materials and Methods

Patients and Specimens
Peripheral blood (PB) samples and fresh tumor specimens were obtained from 73 patients with NSCLC at Guangdong General Hospital. Of these, 42 large (diameter !10 mm 3 ) fresh tumor specimens were obtained from surgical procedures and 31 small biopsy specimens were provided by patients who received immunotherapy. To study the distribution of high-PD-1-, high-interferon gamma (IFN-g)-, and high-tumor necrosis factor-a (TNF-a)-expressing CD8 T cells and high-PD-L1-expressing Tregs (PD-L1
hi Tregs), we collected normal lung tissue, tumor tissue, and PB samples from the same patients. PB was collected before surgery and without radiotherapy or chemotherapy. The clinicopathological features of the patients in the four groups after immunologic classification in this study are shown in Supplementary 
Ethical Statement
All patients received oral and written information and gave written consent before inclusion. The study was approved by the Scientific Ethics Committee of Guangdong General Hospital and Guangdong Academy of Medical Sciences.
Cell Isolation
PB mononuclear cells were collected from peripheral venous blood (8 mL) by using Ficoll-Paque density gradient centrifugation of patients with NSCLC. Whole blood was drawn in heparinized tubes with the FicollHypaque gradient (GE Healthcare Life Sciences, Pittsburgh, PA) and centrifuged for 20 minutes at 2000 rpm, and then cryopreserved at À80ºC. The PB mononuclear cells were thawed for FCM, washed in AIM-V medium (Invitrogen, Carlsbad, CA), counted in the presence of trypan blue dye to evaluate viability, and used immediately. TILs were collected from fresh NSCLC tissue samples and dispersed by using type IV collagenase (Life Technologies, Carlsbad, CA) and hyaluronidase (10 ng/ mL) at 37 C with gentle agitation for 2 to 3 hours. Single cells were isolated by using a Ficoll-Hypaque gradient and cultured in 12-well plates with culture medium consisting of Roswell Park Memorial Institute (RPMI) 1640 medium (HyClone, Logan, UT), 2 mmol/L L-glutamine, penicillin (100 U/mL), streptomycin (100 mg/mL), 10% heat-inactivated human serum, and 100 U/ mL interleukin-2. TILs were cryopreserved until further analysis.
Cell Culture
The NSCLC cell lines H1650, H23, A549, H460, and H1299 were obtained from the American Type Culture Collection (Manassas, VA) and cultured in complete RPMI 1640 medium with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 mg/mL streptomycin (Gibco, Carlsbad, CA). Blood mononuclear cells were thawed into RPMI-1640 medium supplemented with 10% FBS, 100 U/mL penicillin, 100 mg/mL streptomycin, 50 IU/mL recombinant human interleukin-2 (IL-2), and 1% (10 mg/mL) DNase (Takara Bio, Kusatsu, Japan). TILs were washed and cultured in RPMI-1640 medium supplemented with 10% FBS containing IL-2 (100 U/mL). After 3 days the expanded TILs were extensively washed and fed with IL-2-containing medium for 6 days. For the PD-1/ PD-L1 blockade assay, the TILs and PB mononuclear CD8-positive T cells were cultured (1Â10 5 per well) with 10 mg/mL anti-PD-1 (clone MIH4, eBioscience, San Diego, CA), anti-PD-L1 (clone MIH1, eBioscience), and their isotype control immunoglobulin G (IgG) (eBioscience). After 96 hours, the cells were collected and analyzed by FCM.
Cytotoxicity Assay
The cytotoxic activity of TILs in killing NSCLC cells after stimulation by anti-PD-1 and anti-PD-L1 was measured by a conventional 51 Cr release assay as previously described. 24 The ratios of TILs to tumor cells (effector-to-target ratios) used were 1:10, 1:2, and 2:1. The effector cells were then mixed at various ratios with 51 Cr-labeled target cells for 96 hours at 37 C. Spontaneous release of 51 Cr was determined by incubating the target cells with medium alone, and maximum release was determined by adding Triton X-100 to a final concentration of 5%. The percentage of specific lysis was calculated as follows: 100 Â [(experimental release -spontaneous release)/(maximum release -spontaneous release)].
FCM and Antibodies
The expression of cell surface and intracellular proteins was assessed with the following antibodies: PD-1-P-phycoerythrin-Cyanine 7 (clone eBioJ105, eBioscience), PD-1 allophycocyanin (APC) (clone J43, eBioscience), PD-L1-P-phycoerythrin (clone MIH1, eBioscience), CD8-fluorescein isothiocyanate (clone 3B5, Thermo Fisher Scientific, Waltham, MA), CD4-fluorescein isothiocyanate (clone RM4-5, eBioscience), CD25-APC (clone PC61.5, eBioscience), IFN-g-PerCP-cyanine 5.5 (clone 4S.B3, eBioscience), and TNF-a-APC (clone MAb11, eBioscience). The T cells surface proteins being detected were incubated in the dark at room temperature for 30 minutes, washed once in fluorescenceactivated cell sorting (FACS) buffer (0.05% phosphatebuffered saline, 2 mM fetal calf serum, ethylenediaminetetraacetic acid, and 0.01% sodium azide), and fixed with 2% formaldehyde. For the analysis of intracellular cytokine production, after cell surface staining, cells were permeabilized with FACS permeabilizing solution per the manufacturer's guidelines. After a 10-minute incubation, cells were washed with the FACS buffer. Cells were then incubated with anti-IL-2, anti-IFN-g, or anti-TNF-a for 30 minutes in the dark at room temperature. Cells were washed once and then fixed with 2% formaldehyde.
IHC
Tumor tissue samples were fixed in formalin and embedded in paraffin wax. NSCLC tissue samples were cut into 5-mm-thick slices and baked for 60 minutes in a 60 C dehydration oven. Antigen retrieval was performed in a microwave oven in citrate buffer (pH6.0). Inhibition of nonspecific binding was achieved with 10% normal goat serum (Tian Gen, People's Republic of China). Slides were incubated overnight at 4 C with anti-CD8a mAb (Abnova, Walnut, CA) at 1:100 and anti-PD-L1 mAb (clone SP142, Spring Bioscience, Pleasanton, CA) at 1:100, followed by horseradish peroxidase-labeled secondary antibodies (Santa Cruz Biotechnology, Dallas, TX). For the PD-L1 antibody, samples with less than 1% cells were identified as PD-L1-negative, and those with more than 1% of the total tumor cells were identified as PD-L1-positive.
IF Staining
Fresh NSCLC tissue samples were cryosectioned into 5-mM sections and kept at À80 C until staining. Before the IF staining, slides were incubated in 4% paraformaldehyde for 10 minutes. Slides were incubated with the following antibodies at the indicated dilutions: anti-PD-1 mAb (Cell Marque, Clone MRQ-22, Rocklin, CA) (dilution 1:100), anti-CD8a mAb (Abnova, USA) (dilution 1:100), and anti-PD-L1 mAb (clone SP142, Spring Bioscience) (dilution 1:100). Alexa Fluor 488-conjugated goat antimouse IgG, or Dylight 649-conjugated goat antirabbit IgG (Santa Cruz Biotechnology) were used as secondary antibodies. Images were acquired using a Leica DM 4000 B microscope (Leica Biosystems, Nussloch, Germany).
Western Blot Analysis
For Western blot analysis, proteins were extracted from the following NSCLC cell lines: H549, H23, H1299, and A549. Aliquots of 30 mL were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (4%-12%) and transferred to Hybond-Cextra nitrocellulose membranes (Milipore, Bedford, MA). The membranes were blocked in phosphate-buffered saline-Tween-20 (0.03%) with 5% milk at room temperature (for 1 hour) and incubated with anti-PD-L1 antibody (Cell Signaling Technology, Danvers, MA) and anti-glyceraldehyde-3-phosphate dehydrogenase (Santa Cruz) at room temperature for 1 hour, followed by incubation in horseradish peroxidase-conjugated secondary antibodies.
Statistical Analysis
For in vitro studies, quantitative data were analyzed using GraphPad Prism 5. The association of PD-1-positive CD8 T cells and PD-L1-expressing Tregs with patient characteristics, including EFGR mutation status, was examined with the Wilcoxon rank sum test (two sided) and analyzed with SPSS 13.0 software (SPSS Inc., Chicago, IL). For FACS analysis, statistical comparisons of different T-cell subpopulations in the same patients were performed by using the paired t test. One-way analysis of variance with the Newman-Keuls test was used in multiple comparisons. Correlations between different immune markers were analyzed by Spearman's rank correlation test. A p value less than 0.05 was considered statistically significant.
Results
Study Cohort
Between April 2014 and May 2017, a total of 73 NSCLC PB samples and fresh tumor specimens were collected for study. Of these, 42 large (diameter !10 mm 3 ) fresh NSCLC tumor specimens were obtained from surgical procedures to study various kinds of TILs. TILs were identified by FCM, IF staining, and IHC. Spearman's rank correlation test was used to assay the association between FCM and IF staining assay. According to the density of PD-L1-positive CD25-positive CD4-positive Tregs and PD-1 TILs in NSCLC, we performed immunologic classification of the patients into four groups. To confirm which immunologic group of patients was the most sensitive to PD-1 blockade immunotherapy, 31 small biopsy specimens from patients who received immunotherapy (pembrolizumab or nivolumab) were analyzed by IHC and IF, and 25 of them had evaluable objective responses (Fig. 1) .
Identification of PD-L1-Expressing CD25-Positive CD4-Positive Tregs and PD-1-Positive TILs in NSCLC
The expression of PD-L1 in CD25-positive CD4-positive Tregs plays an important role in many diseases and infections, 23, 25 and studies have shown that PD-L1 expression in TILs is correlated with objective responses. 26 To Fig. 2A [white arrows] ). Cell suspensions from tumor, blood, and fresh normal lung tissue samples were used to measure the percentages of PD-L1-positive CD25-positive CD4-positive Tregs. We found that the percentages and numbers of PD-L1-expressing CD25-positive CD4-positive Tregs were significantly higher in tumor tissue than in blood and normal tissue (p < 0.05), as determined by FCM ( Fig. 2B and Supplementary Fig. 1A and B) . To understand the distribution of PD-L1-positive TILs in NSCLC, we assessed the expression of PD-L1 by IHC in serial sections and found that the distribution of PD-L1-positive TILs was similar to that of CD4-positive T cells (Fig. 2C) .
Mismatch repair in coding regions may lead to the synthesis of neoantigens recognized by CD8-positive T cells. 27 To determine whether the expression of PD-1 on CD8 TILs was the result of immunologic escape in the tumor microenvironment 28 , we examined the PD-1-positive CD8 T cells in tumor and adjacent normal tissue by IF staining (Fig. 2D) . We studied the frequency and absolute cell numbers of PD-1-positive CD8 TILs in blood, normal lung tissue, and lung cancer tissue and found that they significantly higher in tumor tissue than in blood and normal tissue (a mean of PD-1-positive CD8 TILs in tumor tissue versus blood versus normal tissue of 40.2% versus 24.5% versus 23.7% [p < 0.05]) ( Fig. 2E and Supplementary Fig. 1C and D) . In addition, patients with a high frequency of PD-1-positive CD8 TILs (mean !40.2% in total CD8-positive TILs) were more likely to have lower frequencies of TNF-a-and IFN-g-producing CD8 TILs in tumors (p < 0.05) ( Supplementary Fig. 1E and F). Moreover, we also found that the density of PD-L1-positive Tregs and PD-1-positive CD8 T cells determined by FCM was significantly correlated with IF staining assay ( Fig. 2F and G) . These data suggested that CD8 TILs with high frequency and absolute cell numbers of PD-1 expression were exhausted in the immune response.
Immunologic Fig. 2B ). The PD-1 hi PD-L1 hi subset of patients had both high frequencies of PD-1-expressing CD8 T cells and PD-L1-expressing Tregs ( Supplementary Fig. 2C and D) and the percentages of IFN-g-and TNF-a-expressing CD8 cells were significantly lower in PD-1 hi PD-L1 hi than in the other three subsets of patients ( Supplementary Fig. 2E  and F) . Regarding the correlation of each group in tumors with the clinicopathologic characteristics of the patients with NSCLC, our results showed that the patient number in each group was not significantly correlated with age, sex, smoking status, disease stage, histological type, or Eastern Cooperative Oncology Group performance status (see Supplementary Table 1) . Although high expression of PD-L1 has been reported to be associated with the presence of EGFR mutations in surgically resected NSCLCs, 30 in our study, the percentages of PD-L1-positive CD25-positive CD4-positive and PD-1-positive CD8 TILs were not associated with the presence of EGFR mutations in NSCLC (data not shown).
Density of PD-L1-Positive Tregs Was Correlated with CD8 T-Cell Exhaustion in the Tumor Microenvironment
We next investigated whether the frequency of PD-L1-positive CD25-positive CD4-positive TILs was correlated with CD8 T-cell exhaustion in the tumor microenvironment. Our results showed that the density of PD-L1-positive Tregs was significantly correlated with the percentage of PD-1-positive CD8 TILs cells in TILs (Fig. 3A) . Moreover, a high percentage of PD-L1-positive CD25-positive CD4-positive TILs (Mean ! 6.3% in total CD3-positive TILs) was negatively correlated with the frequencies of IFN-g-and TNF-a-producing CD8 T cells in the tumor microenvironment (Fig. 3B and  C) . The frequencies of IFN-g-and TNF-a-producing CD8 T cells were higher in the patients with a low frequency of PD-L1-positive Tregs (Mean < 6.3%) than in those with a high frequency of PD-L1-positive Tregs (Mean ! 6.3%) (Fig. 3D ) Overall, these data indicated that the density of PD-L1-positive Tregs was correlated with CD8 T-cell exhaustion in the tumor microenvironment.
CD8 TILs' Killing Effect Induced by PD-1/PD-L1 Blockade Was Influenced by PD-1-Positive CD8-Positive and PD-L1-Positive CD25-Positive CD4-Positive TILs Next, we aimed to determine whether the frequencies of PD-1-positive CD8 and PD-L1-positive CD25-positive CD4-positive TILs were related to the immune-response of TILs to tumor cells after PD-1/PD-L1 blockade. For this purpose, we first assessed the expression of PD-L1 in the H1299, PC9, H23, and A549 NSCLC cell lines and found that PD-L1 expression was high in PC9 cells and low in H23 cells (Fig. 4A) . We then cocultured TILs from patients with high-PD-L1-expressing NSCLC PC9 cells or low-PD-L1-expressing NSCLC H23 cells in vitro. The in vitro cytolytic assays demonstrated that compared with in the IgG control and TILs-only groups, the TILs cotreated with PD-1/PD-L1 antibody had a significantly enhanced ability to kill PC9 and H23 cells in the PD-1 hi PD-L1 hi TILs group, but not in other three groups (Fig. 4B and C) . The expression of PD-L1 in tumor cells is correlated with improved efficacy of PD-1 blockade therapy. [29] [30] [31] To understand whether the expression of PD-L1 in tumor cells was an important factor affecting the killing efficacy of TILs, we compared the killing efficacy of TILs in H23 and PC9 cells. Our results showed that the cell killing efficacy was higher in PD-1 hi PD-L1 hi TILs cotreated with PC9 cells than in H23 cells by anti-PD-1 (p < 0.05) and anti-PD-L1 (p < 0.001); however there were no statistically significant differences in the PD-1 hi PD-L1 lo , PD-1 lo PD-L1 hi , and PD-1 lo PD-L1 lo coculture groups ( Fig. 4D and E) . (Fig. 4F) (Fig. 4H ).
Discussion
Accumulating evidence suggests that PD-1/PD-L1-targeting antibodies are effective for treating many types of human cancer, including NSCLC. [1] [2] [3] However, the status of PD-L1 expression on tumor cells alone is not sufficient to identify patients who might respond to PD-1/PD-L1 blockade immunotherapy; mismatch repair and the presence of TILs and cytokines in tumor samples could also influence the immune response. 4, 32 In the present study, we investigated whether the frequency of PD-1 and PD-L1 expression in TILs could lead to different responses to PD-1/PD-L1 blockade (PD-1 hi PD-L1 hi ) in TILs that was responsive to PD-1/PD-L1 blockade, which indicated that the frequency of PD-1-expressing CD8 cells and PD-L1-expressing Tregs in TILs can serve as an additional diagnostic marker to supplement PD-L1 expression in tumor cells for the identification of patients who might benefit from PD1/PD-L1 blockade immunotherapy.
Many reasons can lead to the immune escape of tumors, such as the loss of tumor antigen expression, 31, 33 increased expression of coinhibitory receptors in TILs (PD-1/PD-L1 and cytotoxic T-lymphocyte associated protein 4), and immunosuppression of effector T cells mediated by infiltrating Tregs and myeloid-derived suppressor cells. [34] [35] [36] PD-1 hi CD8 T cells work as a dysfunctional T-cell subset; the increased frequency of PD-1 hi CD8 T cells could result in immunosuppression in chronic infections and in cancer. 37, 38 The genomic landscape and the presence of preexisting CD8-positive T cells and cytokines in tumor samples could influence the response to immunotherapy. 39 NSCLC (including lung squamous and lung adenocarcinoma) has a high mutational burden compared with other solid tumors, and somatic mutations can give rise to neoantigens. 40 The infiltration of CD8 cells at the site of the tumor is suggestive of a specific immune response to tumor antigens. In our study, CD8 T cells were detected in all the 73 fresh NSCLC tissue samples. PD-1/PD-L1 blockade immunotherapy has shown clinical efficacy in several tumors, including NSCLC, by rescue of T-cell exhaustion through the PD-1/PD-L1 pathway. However, the expression of PD-L1 in tumors stained by IHC was affected by tumor heterogeneity, and the detection of PD-L1 expression in tumors alone does not accurately assess the immune status in the tumor microenvironment. Therefore, additional diagnostic approaches are needed to predict who might respond to PD-1/PD-L1 blockade immunotherapy. Our study suggests that there is a subset of patients with both high frequency of PD-1-expressing CD8 and PD-L1-expressing TILs who have a greater PD-1/PD-L1 pathway dependence on CD8 T-cell exhaustion, and PD-1/PD-L1 blockade could induce more cancer cellkilling effects in patients with both PD-1 hi CD8 and PD-L1 hi Tregs. Our findings suggested that the different frequencies of preexisting PD-1 hi CD8 and PD-L1 hi Tregs can serve as a diagnostic factor to supplement PD-L1 expression in tumor cells for predicting the response to PD-1/PD-L1 blockade immunotherapy.
